Stephenson Cancer Center - Cancer Center Support Grant

史蒂芬森癌症中心 - 癌症中心支持补助金

• 批准号: 10372607
• 负责人: ROBERT S. MANNEL
• 金额: $ 11.5万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10372607
• 关键词: Address; Age; American Indians; Award; COVID-19; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Death Rates; Catchment Area; Categories; Centers for Disease Control and Prevention (U.S.); Clinic; Clinical Research; Clinical Trials Network; Collaborations; Communities; Community Outreach; Development; Diagnosis; Enrollment; Funding; Goals; Health Professional; Health Sciences; Incidence; Institution; Intervention; Investigational Therapies; Journals; Lead; Malignant Neoplasms; Mission; NCI-Designated Cancer Center; National Clinical Trials Network; Nature; Oklahoma; Parents; Patient-Centered Care; Patients; Peer Review; Publications; Publishing; Reporting; Research; Research Personnel; Role; Rural Population; Scientist; Site; Source; Strategic Planning; Training; Training and Education; Translating; Universities; cancer prevention; career; community based research; community engagement; community setting; experience; member; mortality; next generation; novel; treatment trial

Parent Award ABSTRACT The Stephenson Cancer Center (SCC) at the University of Oklahoma continued to grow and mature during its third year of NCI Cancer Center Support Grant (CCSG) funding. As the state's only NCI-Designated Cancer Center, the SCC has a critical mission of eliminating cancer in Oklahoma and beyond through: 1) providing the highest level of research-driven, patient centered care; 2) translating novel discoveries to the clinic and community settings; 3) engaging the community and addressing cancer problems prevalent in the catchment area; and 4) training the next generation of cancer researchers and health professionals. This mission is especially critical in Oklahoma, which has the fourth highest age-adjusted cancer death rate (177.3 per 100,000) among all states (CDC). Efforts to advance this mission are guided by a five-year Strategic Plan (2018-22) and supported by significant institutional commitments on the part of the University and State. The SCC currently has 131 members (71 Full and 60 Associate), representing 32 different academic departments at the OU Health Sciences Center (OUHSC) and OU Norman campuses. These cancer center members published 295 cancer-focused publications in peer reviewed journals. Of these, 22% involved Intra-Programmatic and 9% Inter-Programmatic collaborations. Notably, both of these percentages dipped significantly in 2020, perhaps reflective of obstacles to collaborating in the era of COVID-19. SCC member publications continued to reflect significant collaboration with scientists at other institutions (80%) and, within that category, at other NCI-Designated Cancer Centers (50%). Research at the SCC continues to reflect a strong focus on cancer problems prevalent in Oklahoma, the SCC's catchment area, and especially the state's large American Indian and rural populations that experience significantly higher cancer incidence and mortality rates. The SCC continues to be a national leader in clinical research. During the reporting period, the SCC had 666 accruals to interventional treatment trials and 634 accruals to interventional non- treatment trials. The SCC continues to be the top accruing site in the NCI's National Clinical Trials Network (NCTN), enrolling 288 patients to National Group trials in CY2020. During the reporting period, the SCC was a lead partner in an awarded consortium application (UM1CA186689) for the NCI Experimental Therapeutics Clinical Trials Network (ETCTN), thereby achieving a primary goal in the SCC's 2018-22 Strategic Plan. Activities in the SCC's Education, Training and Career Enhancement (ETCE) Core have grown significantly, highlighted by a continued increase in peer-reviewed training funding (see above). The SCC's Community Outreach and Engagement (COE) Core is continuing to add capacity and take a lead role in promoting and coordinating research focused on the SCC catchment area. The SCC continues to be a premier site nationally for conducting community-based research with tribal partners to address the high cancer incidence and mortality rates among American Indians in the state.

家长奖 摘要 俄克拉荷马大学史蒂芬森癌症中心 (SCC) 不断发展壮大 在 NCI 癌症中心支持补助金 (CCSG) 资助的第三年成熟。作为国家的 作为唯一一家 NCI 指定的癌症中心，SCC 肩负着消除癌症的重要使命 俄克拉荷马州及其他地区通过：1）提供最高水平的研究驱动的、耐心的 集中护理； 2）将新发现转化为临床和社区环境； 3）吸引人 社区并解决流域内普遍存在的癌症问题； 4）培训 下一代癌症研究人员和卫生专业人员。这次任务特别 俄克拉荷马州的这一情况至关重要，该州的年龄调整癌症死亡率排名第四（每人 177.3 人） 100,000）所有州（CDC）。推进这一使命的努力以五年计划为指导 战略计划（2018-22）并得到了重大机构承诺的支持 大学和国家。 SCC 目前有 131 名会员（71 名正式会员和 60 名准会员），代表 32 个不同的领域。 OU 健康科学中心 (OUHSC) 和 OU Norman 的学术部门 校园。这些癌症中心成员在同行中发表了 295 篇以癌症为主题的出版物 审阅期刊。其中，22% 涉及程序内，9% 涉及程序间 合作。值得注意的是，这两个百分比在 2020 年均大幅下降，也许 反映了 COVID-19 时代合作的障碍。 SCC会员出版物 继续反映出与其他机构（80%）的科学家的重要合作，并且 该类别在其他 NCI 指定癌症中心 (50%)。 SCC 的研究仍在继续 反映对俄克拉荷马州（SCC 辖区）普遍存在的癌症问题的强烈关注， 尤其是该州大量的美洲印第安人和农村人口 癌症发病率和死亡率显着升高。 SCC 继续在临床研究方面处于全国领先地位。报告期内， SCC 有 666 项介入治疗试验应计项目和 634 项介入非治疗试验应计项目 治疗试验。 SCC 仍然是 NCI 全国临床中累积最多的站点 试验网络 (NCTN)，在 2020 年招募 288 名患者参加国家组试验。期间 报告期内，SCC是一项获奖联合体申请的主要合作伙伴 (UM1CA186689) NCI 实验治疗临床试验网络 (ETCTN)， 从而实现 SCC 2018-22 战略计划中的主要目标。 SCC 的活动 教育、培训和职业提升（ETCE）核心显着增长， 突出表现是同行评审培训资金的持续增加（见上文）。 SCC 的 社区外展和参与 (COE) 核心正在继续增加容量并采取 在促进和协调以 SCC 流域为重点的研究方面发挥主导作用。南卡罗来纳州委员会 仍然是全国与部落进行社区研究的首要场所 合作伙伴解决美洲印第安人的高癌症发病率和死亡率问题 国家。